The V1/V2 loop of HIV-1 gp120 is necessary for Tat binding and consequent modulation of virus entry

Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects

(2012) R. E. Nettles et al.   JOURNAL OF INFECTIOUS DISEASES

HIV-1 Tat Promotes Integrin-Mediated HIV Transmission to Dendritic Cells by Binding Env Spikes and Competes Neutralization by Anti-HIV Antibodies

(2012) Paolo Monini et al.   PLoS One

Safety, Efficacy, and Pharmacokinetics of TBR-652, a CCR5/CCR2 Antagonist, in HIV-1–Infected, Treatment-Experienced, CCR5 Antagonist–Naive Subjects

(2011) Jacob Lalezari et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection

(2010) C. J. Bruno et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

An improved PCR method for detection of HIV-1 proviral DNA of a wide range of subtypes and recombinant forms circulating globally

(2010) Jürgen Weidner et al.   JOURNAL OF VIROLOGICAL METHODS

Immobilized HIV-1 Tat protein promotes gene transfer via a transactivation-independent mechanism which requires binding of Tat to viral particles

(2009) Filomena Nappi et al.   JOURNAL OF GENE MEDICINE

The HIV-1 Envelope Glycoprotein gp120 Features Four Heparan Sulfate Binding Domains, Including the Co-receptor Binding Site

(2008) Elodie Crublet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load

(2008) Mauro S Malnati et al.   Nature Protocols

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE